Your browser doesn't support javascript.
loading
Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPP
William J Hulme; Elizabeth J Williamson; Elsie Horne; Amelia CA Green; Linda Nab; Ruth Keogh; Edward PK Parker; Venexia M Walker; Tom M Palmer; Helen J Curtis; Milan Wiedemann; Christine Cunningham; Alex J Walker; Louis Fisher; Brian MacKenna; Christopher T Rentsch; Anna Schultze; Krishnan Bhaskaran; John Tazare; Laurie A Tomlinson; Helen I McDonald; Caroline E Morton; Richard Croker; Colm D Andrews; Lisa EM Hopcroft; Robin Y Park; Jon Massey; Amir Mehrkar; Jessica Morley; Sebastian CJ Bacon; David Evans; Peter Inglesby; George Hickman; Simon Davy; Iaim Dillingham; Tom Ward; Viyaasan Mahalingasivam; Bang Zheng; Ian J Douglas; Stephen JW Evans; Christopher Bates; Jonathan AC Sterne; Miguel A Hernan; Ben Goldacre.
Afiliação
  • William J Hulme; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Elizabeth J Williamson; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Elsie Horne; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK
  • Amelia CA Green; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Linda Nab; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Ruth Keogh; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Edward PK Parker; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Venexia M Walker; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho
  • Tom M Palmer; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho
  • Helen J Curtis; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Milan Wiedemann; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Christine Cunningham; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Alex J Walker; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Louis Fisher; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Brian MacKenna; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Christopher T Rentsch; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Anna Schultze; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Krishnan Bhaskaran; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • John Tazare; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Laurie A Tomlinson; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Helen I McDonald; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Caroline E Morton; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Richard Croker; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Colm D Andrews; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Lisa EM Hopcroft; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Robin Y Park; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Jon Massey; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Amir Mehrkar; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Jessica Morley; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Sebastian CJ Bacon; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • David Evans; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Peter Inglesby; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • George Hickman; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Simon Davy; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Iaim Dillingham; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Tom Ward; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
  • Viyaasan Mahalingasivam; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Bang Zheng; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Ian J Douglas; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Stephen JW Evans; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
  • Christopher Bates; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Jonathan AC Sterne; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; H
  • Miguel A Hernan; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health,
  • Ben Goldacre; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22276026
ABSTRACT
BackgroundThe UK COVID-19 vaccination programme delivered its first "booster" doses in September 2021, initially in groups at high risk of severe disease then across the adult population. The BNT162b2 Pfizer-BioNTech vaccine was used initially, with Moderna mRNA-1273 subsequently also used. MethodsWe used the OpenSAFELY-TPP database, covering 40% of English primary care practices and linked to national coronavirus surveillance, hospital episodes, and death registry data, to estimate the effectiveness of boosting with BNT162b2 compared with no boosting in eligible adults who had received two primary course vaccine doses between 16 September and 16 December 2021 when the Delta variant of SARS-CoV-2 was dominant. Follow up was for up to 10 weeks. Each booster recipient was matched with an unboosted control on factors relating to booster priority status and prior immunisation. Additional factors were adjusted for in Cox models estimating hazard ratios (HRs). Outcomes were positive SARS-CoV-2 test, COVID-19 hospitalisation, COVID-19 death and non-COVID-9 death. Booster vaccine effectiveness was defined as 1-HR. ResultsAmong 4,352,417 BNT162b2 booster recipients matched with unboosted controls, estimated effectiveness of a booster dose compared with two doses only was 50.7% (95% CI 50.1-51.3) for positive SARS-CoV-2 test, 80.1% (78.3-81.8) for COVID-19 hospitalisation, 88.5% (85.0-91.1) for COVID-19 death, and 80.3% (79.0-81.5) for non-COVID-19 death. Estimated effectiveness was similar among those who had received a BNT162b2 or ChAdOx1-S two-dose primary vaccination course, but effectiveness against severe COVID-19 was slightly lower in those classified as clinically extremely vulnerable (76.3% (73.1-79.1) for COVID-19 hospitalisation, and 85.1% (79.6-89.1) for COVID-19 death). Estimated effectiveness against each outcome was lower in those aged 18-65 years than in those aged 65 and over. ConclusionOur findings are consistent with strong protection of BNT162b2 boosting against positive SARS-CoV-2 test, COVID-19 hospitalisation, and COVID-19 death.
Licença
cc_by
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint